Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

NCT07255846 is registered in ClinicalTrials.gov with Terremoto Biosciences Inc. as lead sponsor.

NCT NCT07255846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07255846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
Lead sponsor
Terremoto Biosciences Inc.
Phase
Phase 1
Overall status
Withdrawn
Start date
December 15, 2025
Completion date
March 31, 2028
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemorrhagic telangiectasia (hht)